| Q35204279 | Antiretroviral therapy: when to start |
| Q38733997 | Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study |
| Q92844412 | Associations between lipids and subclinical coronary atherosclerosis |
| Q30248286 | Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy |
| Q40570472 | Baseline, Time-Updated, and Cumulative HIV Care Metrics for Predicting Acute Myocardial Infarction and All-Cause Mortality |
| Q57180790 | British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 |
| Q39405054 | Cardiovascular Disease Risk Prediction in the HIV Outpatient Study |
| Q92696173 | Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study |
| Q35203971 | Cardiovascular disease in HIV patients: from bench to bedside and backwards. |
| Q41661011 | Cardiovascular disease in HIV: traditional and nontraditional risk factors. |
| Q26777866 | Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk? |
| Q35064091 | Cardiovascular disease risk in an aging HIV population: not just a question of biology. |
| Q35190397 | Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy |
| Q35055172 | Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. |
| Q39165028 | Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer |
| Q92090980 | Coronary Microvascular Dysfunction in HIV: A Review |
| Q41540061 | Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care |
| Q58344631 | Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort |
| Q35995595 | Determinants of Smoking and Quitting in HIV-Infected Individuals |
| Q35473503 | Elevated levels of monocyte activation markers are associated with subclinical atherosclerosis in men with and those without HIV infection |
| Q34553819 | Elevated rates of intracerebral hemorrhage in individuals from a US clinical care HIV cohort |
| Q33998067 | Epidemiology of coronary heart disease in patients with human immunodeficiency virus |
| Q38629009 | Epidemiology of ischemic heart disease in HIV. |
| Q64086650 | Evolving understanding of cardiovascular, cerebrovascular and peripheral arterial disease in people living with HIV and role of novel biomarkers. A study of the Spanish CoRIS cohort, 2004-2015 |
| Q92277511 | Excess Risk for Atherosclerotic Cardiovascular Outcomes Among US Adults With HIV in the Current Era |
| Q96817678 | Frequency of Human Immunodeficiency Virus in Patients Admitted with Acute Stroke |
| Q30239101 | HIV and its relationship to insulin resistance and lipid abnormalities. |
| Q38649363 | HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review |
| Q39392100 | HIV-1-Associated Atherosclerosis: Unraveling the Missing Link |
| Q40656708 | Heart failure in patients with human immunodeficiency virus infection: Epidemiology and management disparities |
| Q36931801 | History of AIDS in HIV-Infected Patients Is Associated With Higher In-Hospital Mortality Following Admission for Acute Myocardial Infarction and Stroke |
| Q91638984 | How Monocytes Contribute to Increased Risk of Atherosclerosis in Virologically-Suppressed HIV-Positive Individuals Receiving Combination Antiretroviral Therapy |
| Q45323599 | Human Immunodeficiency Virus Infection And Hypertension. Is There A Connection? |
| Q40709368 | Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013. |
| Q27028033 | Identifying the appropriate comparison group for HIV-infected individuals |
| Q50095812 | Imaging to End Points: Cardiovascular Disease Risk Assessment in HIV. |
| Q36556082 | Immune activation and cardiovascular disease in chronic HIV infection |
| Q40196920 | Increased Risk of Myocardial Infarction in HIV-Infected Individuals in North America Compared With the General Population |
| Q36957752 | Inflammation, immune activation, and cardiovascular disease in HIV. |
| Q60046139 | Influence of Physical Exercise on Advanced Glycation End Products Levels in Patients Living With the Human Immunodeficiency Virus |
| Q57802126 | Managing HIV infection in patients older than 50 years |
| Q33555718 | Monocyte bioenergetic function is associated with body composition in virologically suppressed HIV-infected women |
| Q33668524 | Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care |
| Q36242636 | Non-Communicable Disease Preventive Screening by HIV Care Model |
| Q38670084 | Prevalence of non-infectious comorbidities in the HIV-positive population in Belgium: a multicenter, retrospective study |
| Q89606626 | Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa |
| Q40163303 | Projecting 10-yr, 20-yr and Lifetime Risks of Cardiovascular Disease in Persons Living with HIV in the US. |
| Q38748465 | Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults. |
| Q38596011 | Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now? |
| Q38261508 | Risk of coronary heart disease in patients with HIV infection |
| Q90261273 | Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis |
| Q26753830 | START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection |
| Q92290439 | Subclinical Atherosclerosis Imaging in People Living with HIV |
| Q92885360 | Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection |
| Q35233159 | Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems |
| Q47989482 | The hidden risk: Incorporating inflammation and HIV serostatus into coronary artery disease screening |
| Q34269272 | Total daily pill burden in HIV-infected patients in the southern United States |
| Q61815713 | Trends in the risk of myocardial infarction among HIV-1-infected individuals relative to the general population in France: Impact of gender and immune status |
| Q39041099 | Types of Myocardial Infarction Among Human Immunodeficiency Virus-Infected Individuals in the United States |
| Q56911208 | Undetectable = Untransmittable and Your Health: The personal benefits of early and continuous therapy for HIV infection |
| Q26749024 | What happens to cardiovascular system behind the undetectable level of HIV viremia? |